Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes
Xiang Hu, Lijuan Yang, Weihui Yu, Wei Pan, Xueqin Chen, Qianqian Li, Jingzong Zhou, Xuejiang Gu Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of ChinaCorrespondence: Xuejiang GuDepartment of Endocrine...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4985859d56b844bc9d26ec08c6141c56 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4985859d56b844bc9d26ec08c6141c56 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4985859d56b844bc9d26ec08c6141c562021-12-02T09:04:30ZAssociation of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes1178-7007https://doaj.org/article/4985859d56b844bc9d26ec08c6141c562020-04-01T00:00:00Zhttps://www.dovepress.com/association-of-serum-fibroblast-growth-factor-23-levels-with-the-prese-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Xiang Hu, Lijuan Yang, Weihui Yu, Wei Pan, Xueqin Chen, Qianqian Li, Jingzong Zhou, Xuejiang Gu Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of ChinaCorrespondence: Xuejiang GuDepartment of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou 325000, Zhejiang Province, People’s Republic of ChinaTel/Fax +86 577 5557 9381Email guxuejiang@wmu.edu.cnPurpose: Fibroblast growth factor (FGF) 23 is currently recognized to be involved in the occurrence and development of metabolic diseases. The present study aimed to investigate the association between serum FGF23 levels and hepatic steatosis, as well as the influence of sleep duration.Patients and Methods: The present study population was selected from patients with diagnosed diabetes hospitalized during February 2018 to April 2019. Serum FGF23 levels were assessed by two-side sandwich enzyme-linked immunosorbent assay. The presence and severity of hepatic steatosis were determined by controlled attenuation parameter (CAP). Hepatic steatosis was determined as CAP≥ 302 dB/m.Results: Serum FGF23 levels were significantly higher in individuals with hepatic steatosis than in those without hepatic steatosis (P=0.004). The present study population was divided into Q1–Q4 according to serum FGF23 quartiles. The risks of hepatic steatosis were increased more than 3 folds in Q2–Q4 (all P< 0.01) compared to Q1. CAP showed an uptrend from Q1 to Q4 (P=0.005), even after adjustment for gender and age (P=0.001). Multivariate variance analyses showed significant differences in CAP among Q1–Q4 (P=0.008) and between individuals with short and long sleep duration (P=0.023), which were independent of each other. Serum FGF23 levels were positively associated with CAP independent of gender, age, total metabolic traits, and sleep duration (P=0.042).Conclusion: Serum FGF23 levels were independently and positively associated with the severity of hepatic steatosis. The associations of serum FGF23 levels and sleep duration with hepatic steatosis were independent of each other.Keywords: fibroblast growth factor 23, hepatic steatosis, controlled attenuation parameter, sleep durationHu XYang LYu WPan WChen XLi QZhou JGu XDove Medical Pressarticlefibroblast growth factor 23hepatic steatosiscontrolled attenuation parameterssleep durationSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 1171-1178 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
fibroblast growth factor 23 hepatic steatosis controlled attenuation parameters sleep duration Specialties of internal medicine RC581-951 |
| spellingShingle |
fibroblast growth factor 23 hepatic steatosis controlled attenuation parameters sleep duration Specialties of internal medicine RC581-951 Hu X Yang L Yu W Pan W Chen X Li Q Zhou J Gu X Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| description |
Xiang Hu, Lijuan Yang, Weihui Yu, Wei Pan, Xueqin Chen, Qianqian Li, Jingzong Zhou, Xuejiang Gu Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of ChinaCorrespondence: Xuejiang GuDepartment of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou 325000, Zhejiang Province, People’s Republic of ChinaTel/Fax +86 577 5557 9381Email guxuejiang@wmu.edu.cnPurpose: Fibroblast growth factor (FGF) 23 is currently recognized to be involved in the occurrence and development of metabolic diseases. The present study aimed to investigate the association between serum FGF23 levels and hepatic steatosis, as well as the influence of sleep duration.Patients and Methods: The present study population was selected from patients with diagnosed diabetes hospitalized during February 2018 to April 2019. Serum FGF23 levels were assessed by two-side sandwich enzyme-linked immunosorbent assay. The presence and severity of hepatic steatosis were determined by controlled attenuation parameter (CAP). Hepatic steatosis was determined as CAP≥ 302 dB/m.Results: Serum FGF23 levels were significantly higher in individuals with hepatic steatosis than in those without hepatic steatosis (P=0.004). The present study population was divided into Q1–Q4 according to serum FGF23 quartiles. The risks of hepatic steatosis were increased more than 3 folds in Q2–Q4 (all P< 0.01) compared to Q1. CAP showed an uptrend from Q1 to Q4 (P=0.005), even after adjustment for gender and age (P=0.001). Multivariate variance analyses showed significant differences in CAP among Q1–Q4 (P=0.008) and between individuals with short and long sleep duration (P=0.023), which were independent of each other. Serum FGF23 levels were positively associated with CAP independent of gender, age, total metabolic traits, and sleep duration (P=0.042).Conclusion: Serum FGF23 levels were independently and positively associated with the severity of hepatic steatosis. The associations of serum FGF23 levels and sleep duration with hepatic steatosis were independent of each other.Keywords: fibroblast growth factor 23, hepatic steatosis, controlled attenuation parameter, sleep duration |
| format |
article |
| author |
Hu X Yang L Yu W Pan W Chen X Li Q Zhou J Gu X |
| author_facet |
Hu X Yang L Yu W Pan W Chen X Li Q Zhou J Gu X |
| author_sort |
Hu X |
| title |
Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| title_short |
Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| title_full |
Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| title_fullStr |
Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| title_full_unstemmed |
Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| title_sort |
association of serum fibroblast growth factor 23 levels with the presence and severity of hepatic steatosis is independent of sleep duration in patients with diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2020 |
| url |
https://doaj.org/article/4985859d56b844bc9d26ec08c6141c56 |
| work_keys_str_mv |
AT hux associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT yangl associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT yuw associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT panw associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT chenx associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT liq associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT zhouj associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes AT gux associationofserumfibroblastgrowthfactor23levelswiththepresenceandseverityofhepaticsteatosisisindependentofsleepdurationinpatientswithdiabetes |
| _version_ |
1718398241605681152 |